Two new drugs from Eli Lilly—Leqembi and donanemab—are showing promising results of slowing Alzheimer's when the disease is in the early stages. Leqembi was approved by the FDA in January; donanemab is currently being considered for FDA approval.
Two new drugs from Eli Lilly—Leqembi and donanemab—are showing promising results of slowing Alzheimer’s when the disease is in the early stages.
The slowing was also the greatest for early-stage patients when they had less of tau, a protein that creates “tangles” in the brain. . “They help slow down progression for patients with early disease which is a large positive step and can help patients live independently longer.”Both Leqembi and donanemab, which are infusions administered intravenously, are the first drugs with clear evidence of slowing cognitive decline in patients with Alzheimer’s.
While these drugs can have severe side effects, experts are hopeful about the positive impact they could have on patients with Alzheimer’s. The Phase 3 Leqembi clinical trials, as well as the trials of donanemab, studied people in this condition.According to Purcell, this emphasizes the importance of accurate, early diagnosis of Alzheimer’s to understand if individuals are eligible for these treatments.
The criteria excluded individuals with health issues like cardiovascular disease, stroke, a history of cancer, and brain injuries., the first approved treatment for Alzheimer's in over 20 years, just 5%, or 12 of the people studied, would have been eligible for the trial after accounting for inclusion and exclusion criteria.What Is Aduhelm?Like Leqembi and donanemab, it works to remove amyloid from the brain and slow the progression of Alzheimer’s.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
New Research Sheds Light on New “Molecular Road” to Alzheimer’s DiseaseGenetic detective work by Brigham researchers sheds light on a promising new treatment strategy for Alzheimer’s disease. Alzheimer’s disease (AD) manifests with a broad spectrum of age onset, symptoms, and severity levels. Lately, the SORL1 gene has garnered interest due to its links with both earl
Read more »
August is the time for a new school year, new experiences, and new anxieties for kidsAugust and September are especially stressful for students heading back to school as they deal with the pressure of school work, change in their summer routine, and sometimes bullying
Read more »
CVS pushes further into generic drugs with Sandoz partnership for new discount HumiraCVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.
Read more »
CVS pushes into making cheaper versions of complex drugs with new discount HumiraCVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.
Read more »
In a new warning, FDA urges people to stop using contaminated eyedropsThere are no reports yet of injuries from the drops, but the agency warned against using the products because of fungal and bacterial contamination.
Read more »
FDA says new COVID-19 vaccines will protect against current strainsThree new variants of COVID-19 are circulating in the United States, but public health officials say the newest vaccines against the virus will provide protection.
Read more »